Development and Future of Automated Insulin Delivery (AID) Systems

Satish K. Garg,Jennifer J. McVean

DOI: https://doi.org/10.1089/dia.2023.0467

2024-02-21

Diabetes Technology & Therapeutics

Abstract:Before the discovery of insulin and diet restriction, the Joslin Clinic reported very high mortality rates for type 1 diabetes (T1D) that ranged from 824 per 1000 individuals aged 10 years to 360 per 1000 individuals aged 30 years. 1 As recently as 40 years ago, medical schools still instructed physicians and other health care providers (HCPs) of the short lifespan (usually not exceeding 35–40 years of age) for people diagnosed with T1D. This was in part due to older and unreliable insulins (beef and pork insulins; both longer-acting {Neutral Protamine Hagedorn (NPH) and Lente/Ultralente insulins} and short-acting insulin {regular insulin}), as well as the lack of reliable glucose monitoring (only urine glucose testing was available). Women with T1D were discouraged from becoming pregnant; many of us may remember the movie "Steel Magnolias" released in 1989 ∼ 35 years ago. Advances in insulin formulations in the past three decades (longer-acting insulins such as glargine, detemir, degludec, and rapid-acting insulins including lispro, aspart, and glulisine) 2,3 have helped in better management of diabetes. Other technological advances in self-monitoring of blood glucose, insulin pumps, and continuous glucose monitoring (CGM) have also significantly improved the glucose control (glycated hemoglobin [HbA1c]), 4 and health outcomes for people with diabetes (PWD). These advances have drastically improved the prevalence of long-term diabetes complications and people with T1D are living longer. However, depending on age at diagnosis and sex, people with T1D still lose 10–17 years of life expectancy. 5,6 Because hyperglycemia and hypoglycemia continue to plague people living with T1D, further technological advancements are required. In this article, we discuss the development and future of the next frontier in the care of PWD: automated insulin delivery (AID) systems which include insulin pumps, CGM, and smart algorithms.

endocrinology & metabolism